HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Hokkaido University Hospital >
Peer-reviewed Journal Articles, etc >

Phase II Study of Continued Trastuzumab Plus Irinotecan in Patients with HER2-positive Gastric Cancer Previously Treated with Trastuzumab (HGCSG 1201)

Files in This Item:

The file(s) associated with this item can be obtained from the following URL:

Title: Phase II Study of Continued Trastuzumab Plus Irinotecan in Patients with HER2-positive Gastric Cancer Previously Treated with Trastuzumab (HGCSG 1201)
Authors: Yasuyuki, Kawamoto Browse this author →KAKEN DB
Satoshi, Yuki Browse this author
Takashi, Meguro Browse this author
Hatanaka, Kazuteru Browse this author
Uebayashi, Minoru Browse this author
Nakamura, Michio Browse this author
Okuda, Hiroyuki Browse this author
Iwanaga, Ichiro Browse this author
Kato, Takashi Browse this author
Nakano, Shintaro Browse this author
Sato, Atsushi Browse this author
Harada, Kazuaki Browse this author
Oba, Koji Browse this author
Sakata, Yuh Browse this author
Sakamoto, Naoya Browse this author →KAKEN DB
Komatsu, Yoshito Browse this author →KAKEN DB
Keywords: gastric cancer
second-line treatment
Issue Date: May-2022
Publisher: Oxford University Press
Journal Title: The Oncologist
Volume: 27
Issue: 5
Start Page: 340
End Page: e374
Publisher DOI: 10.1093/oncolo/oyab062
Abstract: Background The efficacy of irinotecan plus continuous trastuzumab beyond progression in patients with gastric cancer previously treated with trastuzumab plus standard first-line chemotherapy has not been reported. Methods Patients with human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer who were previously treated with trastuzumab received trastuzumab every 3 weeks and irinotecan every 2 weeks. The primary endpoint was the overall response rate (ORR), and the secondary endpoints included progression-free survival (PFS), 6-month survival rates, safety, and subgroup analysis by HER2 status. Results Sixteen patients were enrolled in a 3-year pre-planned registration period. This study was prematurely closed due to poor patient accrual. The ORR and disease control rate were 6.7% (95% CI, 0.2-32.0) and 53.3% (95% CI, 26.6-78.7). The median PFS and overall survival (OS) were 2.4 months (95% CI, 0.0-5.2) and 9.7 months (95% CI, 8.2-11.2), respectively. The most frequently reported grades 3-4 adverse events were neutropenia (40%), anemia (27%), anorexia (33%), and fatigue (33%). Conclusion With only 16 patients enrolled, the present study has very low power to detect any clinical benefit of trastuzumab plus irinotecan beyond disease progression in patients with HER2-positive advanced gastric cancer who previously received trastuzumab. Trial Identifier: UMIN000007636.
Type: article
Appears in Collections:北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Export metadata:

OAI-PMH ( junii2 , jpcoar_1.0 )

MathJax is now OFF:


 - Hokkaido University